Aeglea BioTherapeutics (AGLE) Receives Daily Media Impact Score of 0.10

Media coverage about Aeglea BioTherapeutics (NASDAQ:AGLE) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aeglea BioTherapeutics earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.3634583686104 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Aeglea BioTherapeutics (AGLE) traded up 2.06% during mid-day trading on Friday, hitting $2.97. 29,444 shares of the stock were exchanged. Aeglea BioTherapeutics has a 12-month low of $2.81 and a 12-month high of $10.34. The company has a 50 day moving average of $3.39 and a 200 day moving average of $5.16. The firm’s market cap is $48.86 million.

AGLE has been the topic of a number of research reports. TheStreet downgraded shares of Aeglea BioTherapeutics from a “c-” rating to a “d+” rating in a research report on Friday, May 26th. ValuEngine upgraded shares of Aeglea BioTherapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, Zacks Investment Research upgraded shares of Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a report on Thursday, August 3rd.

ILLEGAL ACTIVITY WARNING: “Aeglea BioTherapeutics (AGLE) Receives Daily Media Impact Score of 0.10” was originally posted by BNB Daily and is owned by of BNB Daily. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/aeglea-biotherapeutics-agle-receiving-somewhat-positive-press-coverage-study-finds-updated.html.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply